Rafferty Asset Management
SRPT icon

Rafferty Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Rafferty Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.22M Sell
123,654
-39,049
-24% -$739K 0.01% 613
2026
Q1 		$3.54M Sell
162,703
-32,554
-17% -$630K 0.01% 485
2025
Q4 		$4.2M Buy
195,257
+20,122
+11% +$424K 0.01% 482
2025
Q3 		$3.37M Buy
175,135
+25,375
+17% +$452K 0.01% 523
2025
Q2 		$2.56M Buy
149,760
+50,655
+51% +$2.16M 0.01% 546
2025
Q1 		$6.32M Sell
99,105
-10,131
-9% -$1.07M 0.03% 322
2024
Q4 		$13.3M Sell
109,236
-28,806
-21% -$3.53M 0.05% 230
2024
Q3 		$17.2M Sell
138,042
-8,542
-6% -$1.18M 0.06% 171
2024
Q2 		$23.2M Buy
146,584
+72,845
+99% +$9.36M 0.09% 123
2024
Q1 		$9.55M Sell
73,739
-29,414
-29% -$3.6M 0.04% 279
2023
Q4 		$9.95M Buy
103,153
+28,973
+39% +$2.78M 0.04% 282
2023
Q3 		$8.99M Buy
74,180
+9,176
+14% +$1.04M 0.05% 250
2023
Q2 		$7.44M Buy
65,004
+16,358
+34% +$2.11M 0.04% 313
2023
Q1 		$6.7M Sell
48,646
-21,988
-31% -$2.85M 0.05% 306
2022
Q4 		$9.15M Buy
70,634
+9,803
+16% +$1.14M 0.08% 201
2022
Q3 		$6.72M Buy
60,831
+504
+0.8% +$50.8K 0.07% 234
2022
Q2 		$4.52M Sell
60,327
-13,566
-18% -$998K 0.04% 297
2022
Q1 		$5.77M Buy
73,893
+7,782
+12% +$596K 0.03% 347
2021
Q4 		$5.95M Buy
66,111
+21,752
+49% +$1.86M 0.03% 308
2021
Q3 		$4.1M Buy
44,359
+14,027
+46% +$1.08M 0.03% 350
2021
Q2 		$2.36M Sell
30,332
-8,192
-21% -$621K 0.01% 639
2021
Q1 		$2.87M Buy
38,524
+32,950
+591% +$3.04M 0.02% 521
2020
Q4 		$950K Sell
5,574
-9,607
-63% -$1.42M 0.01% 516
2020
Q3 		$2.13M Buy
15,181
+9,109
+150% +$1.38M 0.03% 397
2020
Q2 		$974K Buy
6,072
+2,482
+69% +$338K 0.01% 555
2020
Q1 		$351K Sell
3,590
-26,238
-88% -$3M 0.01% 403
2019
Q4 		$3.85M Sell
29,828
-45,686
-61% -$4.61M 0.06% 174
2019
Q3 		$5.69M Buy
75,514
+34,167
+83% +$4.04M 0.09% 139
2019
Q2 		$6.28M Buy
41,347
+3,433
+9% +$417K 0.11% 122
2019
Q1 		$4.52M Buy
+37,914
New +$4.87M 0.07% 154

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Rafferty Asset Management's SRPT Position: Q2 2026 in Review

Rafferty Asset Management reduced its Sarepta Therapeutics (SRPT) stake by 24% in Q2 2026, selling an estimated $739K and leaving 123,654 shares worth $2.22M. The position accounts for 0.01% of the portfolio, ranked #613.

Rafferty Asset Management first reported a position in SRPT in Q1 2019 and has held it in 30 quarters since. The position peaked at $23.2M in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Rafferty Asset Management held 123,654 shares of Sarepta Therapeutics worth $2.22M as of Q2 2026.
  • Rafferty Asset Management sold 39,049 Sarepta Therapeutics shares in Q2 2026, an estimated $739K.
  • Sarepta Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #613 holding.
  • Rafferty Asset Management first reported a position in Sarepta Therapeutics in Q1 2019 and has held it in 30 quarters since.
  • Rafferty Asset Management's Sarepta Therapeutics position peaked at $23.2M in Q2 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.